Unjha Formulations Limited (BOM:531762)
19.26
-0.74 (-3.70%)
At close: May 26, 2026
Unjha Formulations Revenue
In the fiscal year ending March 31, 2026, Unjha Formulations had annual revenue of 157.49M INR with 13.06% growth. Unjha Formulations had revenue of 33.28M in the quarter ending March 31, 2026, with 39.16% growth.
Revenue
157.49M
Revenue Growth
+13.06%
P/S Ratio
0.55
Revenue / Employee
11.25M
Employees
14
Market Cap
86.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 157.49M | 18.19M | 13.06% |
| Mar 31, 2025 | 139.30M | -45.67M | -24.69% |
| Mar 31, 2024 | 184.96M | 53.42M | 40.61% |
| Mar 31, 2023 | 131.54M | -10.24M | -7.22% |
| Mar 31, 2022 | 141.77M | 42.16M | 42.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vivanza Biosciences | 1.16B |
| Beryl Drugs | 176.65M |
| Brawn Biotech | 172.71M |
| Decipher Labs | 148.66M |
| Norris Medicines | 94.44M |
| Colinz Laboratories | 61.36M |
| Ganga Pharmaceuticals | 28.28M |
| Emmessar Biotech & Nutrition | 24.07M |